Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )
16 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )
16 Apr 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in p...
Prof Georgina Long - University of Sydney, Sydney, Australia
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )
13 Apr 2021
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocell...
Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA
Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021
Cemiplimab plus ipilimumab for advanced NSCLC
Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
Cemiplimab plus ipilimumab for advanced NSCLC ( Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea )
7 Apr 2021